Resistin in systemic lupus erythematosus: Relation to lupus nephritis and premature atherosclerosis

Egyptian Rheumatologist

Volumn 34, Issue 4, 2012, Pages 137-146

  Elshishtawy, Heba ^a   Ibrahim, Soha ElDessouki ^a   Helmi, Amir ^a   Farouk, Naglaa ^a   Elshinnawy, Maha A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Atherosclerotic cardiovascular disease; Carotid intima media thickness; Lupus nephritis; Resistin; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL MARKER; RESISTIN;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84880395871     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2012.06.001     Document Type: Article

References (43)

1. Simard J.F., Costenbader K.H. What can epidemiology tell us about systemic lupus erythematosus?. Int J Clin Pract 2007, 61:1170-1180.
2. Molino C., Fabbian F., Longhini C. Clinical approach to lupus nephritis: recent advances. Eur J Int Med 2009, 20(5):447-453.
3. Westerweel P.E., Luyten R.K., Koomans H.A., Derksen R.H., Verhaar M.C. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007, 56:1384-1396.
4. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
5. Ghosh S., Singh A.K., Aruna B., Mukhopadhyay S., Ehtesham N.Z. The genomic organization of mouse resistin reveals major differences from the human resistin: functional Implications. Gene 2003, 305:27-34.
6. Guzik T.J., Mangalat D., Korbut R. Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol 2006, 57(4):505-528.
7. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
8. Migita K., Maeda Y., Miyashita T., Kimura H., Nakamura M., Ishibashi H., et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006, 24:698-701.
9. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:100-105.
10. McTernan P.G., Kusminski C.M., Kumar S. Resistin. Curr Opin Lipidol 2006, 17:170-175.
11. Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS one 2006, 1:e31.
12. Nüsken K.D., Kratzsch J., Wienholz V., Stöhr W., Rascher W., Dötsch J. Circulating resistin concentrations in children depend on renal function. Nephrol Dial Transplant 2006, 21:107-112.
13. Ohmori R., Momiyama Y., Kato R., Taniguchi H., Ogura M., Ayaori M., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. Am Coll Cardiol 2005, 46:379-380.
14. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004, 15(5):1307-1315.
15. Filková M., Haluzík M., Gay S., Šenolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009, 133:157-170.
16. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277. with permission of the American College of Rheumatology. Source: Adapted from Hochberg ME. Updating the American College of Rheumatology revised criteria for classification of Systemic lupus erthymatosus. [letter]. Arthritis Rheum 1997;40:1725, with permission of American College of Rheumatology.
17. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35(6):630-640.
18. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250.
19. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
20. Sabry A., Sheashaa H., El-Husseini A. Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006, 35:148-153.
21. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
22. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476.
23. Aruna B., Ghosh S., Singh A.K., Mande S.C., Srinivas V., Chauhan R., et al. Human recombinant resistin protein displays a tendency to aggregate by forming intermolecular disulfide linkages. Biochemistry 2003, 42:10554-10559.
24. Baker J.F., Morales M., Qatanani M., Cucchiara A., Nackos E., Lazar M.A., et al. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 2011, 38:2369-2375.
25. De Sanctis J.B., Zabaleta M., Bianco N.E., Garmendia J.V., Rivas L. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 2009, 42:272-274.
26. Chung C.P., Long A.G., Solus J.F., Rho Y.H., Oeser A., Raggi P., et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009, 18(9):799-806.
27. Almehed K., Helena Forsblad d'Elia H., Bokarewa M., Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008, 10(1):R15.
28. Hu W.L., Qian S.B., Li J.J. Decreased C-reactive protein induced resistin production in human monocytes by simvastatin. Cytokine 2007, 40:201-206.
29. Malyszko J., Malyszko J.S., Pawlak K., Mysliwiec M. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc 2006, 38:3434-3436.
30. Kielstein J.T., Becker B., Graf S., Brabant G., Haller H., Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003, 42:62-66.
31. Landray M.J., Wheeler D.C., Lip G.Y., Newman D.J., Blann A.D., McGlynn F.J., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004, 43:244-253.
32. Yaturu S., Daberry R.P., Rains J., Jain S., et al. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006, 34:219-223.
33. Kawanami D., Maemura K., Takeda N., Harada T., Nojiri T., Imai Y., et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine endothelial cell interactions. Biochem Biophys Res Commun 2004, 314(2):415-419.
34. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005, 41(4):691-698.
35. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Laza M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
36. Chu S., Ding W., Li K., Pang Y., Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008, 72:1249-1253.
37. Christou A., Skoura M., Kapogiannis P., Marinakos A., Tsoukala M., Paraskevopoulou E., et al. Resistin levels in hypertensive women with impaired renal function. Thromb Res 2011, 2011(127):S134-5. 10.1016/S0049-3848(11)70079-2.
38. Reilly M.P., Wolfe M.L., Rhodes T., Girman C., Mehta N., Rader D.J. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004, 110(7):803-809.
39. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens 2007, 25:1105-1187. Erratum in: J Hyperten 2007;25:1749.
40. Simons P.C., Algra A., Bots M.L., Grobbee D.E., van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART study (second manifestations of arterial disease). Circulation 1999, 100:951-957.
41. Vendrell J., Broch M., Vilarrasa N., Molina A., Gomez J.M., Gutierrez C., et al. Resistin, adiponectin, ghrelin, leptin and proinflammatory cytokines: relationships in obesity. Obes Res 2004, 12:962-971.
42. Makimowicz-McKinnon K., Magder L.S., Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006, 33(12):2458-2463.
43. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.